Phaseline

Targets › VDR

VDR (Vitamin D3 receptor): drug programs, companies and trials

23 programs from 23 companies in 49 trials: 16 Phase 2, 15 Phase 3, 11 Phase 4, 7 Phase 1; Other, Oncology, Immunology; next expected readout Nov 2026.

Nuclear receptor for calcitriol, the active form of vitamin D3 which mediates the action of this vitamin on cells. Enters the nucleus upon vitamin D3 binding where it forms heterodimers with the retinoid X receptor/RXR. The VDR-RXR heterodimers bind to specific response elements on DNA and activate the transcription of vitamin D3-responsive target genes. (UniProt, P11473)

Open in Phaseline: the race on VDR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Chulalongkorn UniversityCalcitriol
Vitamin D receptor agonist
VDRPhase 4Cholestatic Liver DiseaseNov 2026
University of Texas Southwestern Medical CenterErgocalciferol
Vitamin D receptor agonist
VDRPhase 4SarcoidosisDec 2026
Zhejiang Provincial People's HospitalEldecalcitol
Vitamin D receptor agonist
VDRPhase 4SarcopeniaMay 2027
RDC ClinicalCholecalciferol
Vitamin D receptor agonist
VDRPhase 4Healthy Volunteer; COVID-19; Bronchiectasis; Osteoarthritis …Sep 2027
Nishtar Medical UniversityErgocalciferol
Vitamin D receptor agonist
VDRPhase 4Pre-eclampsia–
Riphah International UniversityIntralesional Vitamin D3
Vitamin D3 receptor agonist with immunomodulatory properties
VDRPhase 4Viral Wart–
Sengkang General HospitalErgocalciferol
Vitamin D receptor agonist
VDRPhase 3SarcopeniaDec 2026
Ottawa Hospital Research InstituteVitamin D3 Drops
Vitamin D receptor agonist; 1,000-10,000 units daily based on serum levels
VDRPhase 3Lung CancerDec 2028
University of RochesterErgocalciferol
Vitamin D receptor agonist
VDRPhase 3Stage I Prostate Cancer AJCC v8Apr 2029
Ain Shams UniversityErgocalciferol
Vitamin D receptor agonist
VDRPhase 3Corrosive Injury–
Sohag UniversityErgocalciferol
Vitamin D receptor agonist
VDRPhase 3Scar, Hypertrophic–
Ghufran Dhari AwadCalcitriol
Vitamin D receptor agonist
VDRPhase 2Accelerated Orthodontic Tooth MovementDec 2026
University of ArizonaCalcipotriene
Vitamin D receptor agonist
VDRPhase 2Actinic KeratosisFeb 2027
University of WashingtonCalcitriol
Vitamin D receptor agonist
VDRPhase 2Kidney Failure, ChronicFeb 2027
OPKO HealthCalcifediol (CTAP101)
Vitamin D receptor agonist
VDRPhase 2CKD Stage 3Oct 2027
University of IoanninaAlphacalcidol
Vitamin D receptor agonist (active vitamin D metabolite)
VDRPhase 2Scoliosis; Adolescence–
Alexandria UniversityCalcipotriene
Vitamin D receptor agonist
VDRPhase 2Oral Leukoplakia–
Northwell HealthErgocalciferol
Vitamin D receptor agonist
VDRPhase 2Graves Disease–
Abramson Cancer Center at Penn Medicineparicalcitol
Vitamin D receptor agonist
VDRPhase 1Locally Advanced Unresectable Pancreatic Cancer Treated With ChemoradiotherapyDec 2026
Aga Khan UniversityErgocalciferol
Vitamin D receptor agonist
VDRPhase 1Anovulatory InfertilityDec 2026
University of Alabama at BirminghamVitamin D supplementation
Vitamin D receptor activation; micronutrient supplementation
VDRPhase 1Prematurity; ExtremeMay 2027
Melissa Pugliano-MauroCalcipotriene
Vitamin D receptor agonist
VDRPhase 1Carcinoma, Squamous CellSep 2027
Foundation University Islamabad1,25 DHC injection
Active vitamin D3 (1,25-dihydroxycholecalciferol) - stimulates bone remodeling and osteocl
VDRPhase 1Malocclusion of Anterior TeethDec 2027

Conditions

Sarcopenia (2) COVID-19 (2) Obesity, Childhood (2) Asthma (2) Corrosive Injury (1) Anovulatory Infertility (1) Lung Cancer (1) Graves Disease (1) Accelerated Orthodontic Tooth Movement (1) Healthy Volunteer (1) Bronchiectasis (1) Osteoarthritis (1)

Modalities

small molecule (19)

Companies

Ain Shams University (1) Aga Khan University (1) Ottawa Hospital Research Institute (1) Zhejiang Provincial People's Hospital (1) Northwell Health (1) Ghufran Dhari Awad (1) RDC Clinical (1) Alexandria University (1) University of Washington (1) University of Alabama at Birmingham (1) Foundation University Islamabad (1) University of Ioannina (1) Sohag University (1) University of Arizona (1) Chulalongkorn University (1) Nishtar Medical University (1) Melissa Pugliano-Mauro (1) OPKO Health (1) Riphah International University (1) University of Rochester (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.